Press Releases MedMira Inc.

Equities

Market Closed - Toronto S.E. Other stock markets 02:45:57 2024-07-12 pm EDT			5-day change	1st Jan Change
0.085 ^CAD	+6.25%		+6.25%	-22.73%

Jul. 03	MedMira Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024	CI
Apr. 02	MedMira Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI

Canadian Investment Regulatory Organization Trade Resumption - MIR	23-08-31	AQ
Canadian Investment Regulatory Organization Trading Halt - MIR	23-08-29	AQ
MedMira enters into Partnership with Maternova for USA and Latin America	23-02-21	AQ
MedMira provides Progress Update	22-10-03	EQ
MedMira provides Progress Update	22-10-03	AQ
MedMira Strengthens and Expands Board	22-07-14	AQ
MedMira Reports Third Quarter Results FY2022	22-06-29	AQ
MedMira Receives Patent for its Unique Quantitative Diagnostic System	22-06-06	AQ
MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market	22-05-27	AQ
VYRA™ Product Line Update	22-05-20	GL
MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test	22-05-12	GL
MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test	22-05-12	GL
MedMira receives the CE mark for its Reveal TP (Syphilis) and starts clinical trials in Canada	22-03-10	AQ
MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada	22-03-09	AQ
MedMira Receives CE Marking for its REVEALCOVID-19 PLUS Total Antibody Test	22-02-09	AQ
MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test	22-02-08	AQ
MedMira Provides a Pre-Annual General Meeting Update	22-02-04	AQ
MedMira Reports First Quarter Results FY2022	21-12-30	AQ
MedMira Announces VYRA™ CoV2Flu and Additional Regulatory Opportunities	21-12-21	AQ
MedMira strengthen its Board with New Appointment	21-12-17	AQ

No results for this search